Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

407 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prevalence, distribution and predictive value of XPO1 mutation in a real-life chronic lymphocytic leukaemia cohort.
Tueur G, Lazarian G, Eclache V, Fleury C, Letestu R, Lévy V, Lefebvre V, Collon JF, Zini JM, Thieblemont C, Soussi T, Cymbalista F, Baran-Marszak F. Tueur G, et al. Among authors: thieblemont c. Br J Haematol. 2020 Nov;191(3):e90-e94. doi: 10.1111/bjh.17046. Epub 2020 Aug 13. Br J Haematol. 2020. PMID: 32790071 Free article. No abstract available.
Are myelodysplastic syndromes and acute myeloid leukaemia occurring during the course of lymphoma always therapy related?
Bigenwald C, Harel S, Chevignon F, Roos-Weil D, Bernard OA, Amorim S, Brice P, Adès L, Nloga AM, Sébert M, Braun T, Eclache V, Thieblemont C, Fenaux P. Bigenwald C, et al. Among authors: thieblemont c. Br J Haematol. 2018 Jan;180(2):304-308. doi: 10.1111/bjh.14323. Epub 2016 Sep 23. Br J Haematol. 2018. PMID: 27662562 Free article. No abstract available.
Stabilization of β-catenin upon B-cell receptor signaling promotes NF-kB target genes transcription in mantle cell lymphoma.
Lazarian G, Friedrich C, Quinquenel A, Tran J, Ouriemmi S, Dondi E, Martin A, Mihoub I, Chiron D, Bellanger C, Fleury C, Gélébart P, McCormack E, Ledoux D, Thieblemont C, Marzec J, Gribben JG, Cymbalista F, Varin-Blank N, Gardano L, Baran-Marszak F. Lazarian G, et al. Among authors: thieblemont c. Oncogene. 2020 Apr;39(14):2934-2947. doi: 10.1038/s41388-020-1183-x. Epub 2020 Feb 7. Oncogene. 2020. PMID: 32034308
Analysis of a cohort of 279 patients with hairy-cell leukemia (HCL): 10 years of follow-up.
Paillassa J, Cornet E, Noel S, Tomowiak C, Lepretre S, Vaudaux S, Dupuis J, Devidas A, Joly B, Petitdidier-Lionnet C, Haiat S, Mariette C, Thieblemont C, Decaudin D, Validire-Charpy P, Drenou B, Eisenmann JC, Uribe MO, Olivrie A, Touati M, Lambotte O, Hermine O, Karsenti JM, Feugier P, Vaillant W, Gutnecht J, Lippert E, Huysman F, Ghomari K, Boubaya M, Levy V, Riou J, Damaj G, Tanguy-Schmidt A, Hunault-Berger M, Troussard X. Paillassa J, et al. Among authors: thieblemont c. Blood Cancer J. 2020 May 27;10(5):62. doi: 10.1038/s41408-020-0328-z. Blood Cancer J. 2020. PMID: 32461544 Free PMC article.
Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia.
Letestu R, Dahmani A, Boubaya M, Baseggio L, Campos L, Chatelain B, Debliquis A, Drénou B, Jacob MC, Legac E, Le Garff-Tavernier M, Lhoumeau AC, Quiney C, Robillard N, Ticchioni M, Aanei C, Katsahian S, Delepine R, Vaudaux S, Rouillé V, Béné MC, Dartigeas C, Van Den Neste E, Leprêtre S, Feugier P, Cartron G, Leblond V, Lévy V, Cymbalista F; French Innovative Leukemia Organization (FILO). Letestu R, et al. Leukemia. 2021 Jun;35(6):1597-1609. doi: 10.1038/s41375-020-01009-z. Epub 2020 Sep 15. Leukemia. 2021. PMID: 32934355
Clinical, biological, and molecular genetic features of Richter syndrome and prognostic significance: A study of the French Innovative Leukemia Organization.
Moulin C, Guillemin F, Remen T, Bouclet F, Hergalant S, Quinquenel A, Dartigeas C, Tausch E, Lazarian G, Blanchet O, Lomazzi S, Chapiro E, Schneider C, Nguyen-Khac F, Davi F, Hunault M, Tomowiak C, Roos-Weil D, Siebert R, Thieblemont C, Cymbalista F, Laribi K, Béné MC, Stilgenbauer S, Guièze R, Feugier P, Broséus J. Moulin C, et al. Among authors: thieblemont c. Am J Hematol. 2021 Sep 1;96(9):E311-E314. doi: 10.1002/ajh.26239. Epub 2021 Jun 2. Am J Hematol. 2021. PMID: 34000073 Free article. No abstract available.
Molecular characterization of Richter syndrome identifies de novo diffuse large B-cell lymphomas with poor prognosis.
Broséus J, Hergalant S, Vogt J, Tausch E, Kreuz M, Mottok A, Schneider C, Dartigeas C, Roos-Weil D, Quinquenel A, Moulin C, Ott G, Blanchet O, Tomowiak C, Lazarian G, Rouyer P, Chteinberg E, Bernhart SH, Tournilhac O, Gauchotte G, Lomazzi S, Chapiro E, Nguyen-Khac F, Chery C, Davi F, Hunault M, Houlgatte R, Rosenwald A, Delmer A, Meyre D, Béné MC, Thieblemont C, Lichter P, Ammerpohl O, Guéant JL; ICGC MMML-Seq Consortium; Guièze R, Martin-Subero JI, Cymbalista F, Feugier P, Siebert R, Stilgenbauer S. Broséus J, et al. Among authors: thieblemont c. Nat Commun. 2023 Jan 19;14(1):309. doi: 10.1038/s41467-022-34642-6. Nat Commun. 2023. PMID: 36658118 Free PMC article.
Brentuximab vedotin in heavily treated Hodgkin and anaplastic large-cell lymphoma, a single centre study on 45 patients.
Monjanel H, Deville L, Ram-Wolff C, Venon MD, Franchi P, Benet C, de Kerviler E, Malphettes M, Thieblemont C, Brice P. Monjanel H, et al. Among authors: thieblemont c. Br J Haematol. 2014 Jul;166(2):306-8. doi: 10.1111/bjh.12849. Epub 2014 Mar 27. Br J Haematol. 2014. PMID: 24673542 Free article. Clinical Trial. No abstract available.
407 results